We’re In The News

As a respected nonprofit health research center, our views are often quoted in the media, including newspapers, magazines, TV, radio, and websites. We also write articles and blogs for a number of different and highly respected newspapers, magazines, and popular websites, and we are published in prestigious medical journals and health policy publications. We frequently express our policy views in letters to government officials and public comments to federal agencies and we sometimes release statements or press releases on newsworthy issues.

Please e-mail info@center4research.org or call 202-223-4000 with your inquiries. We can assist you with scheduling interviews with the NCHR President, Dr. Diana Zuckerman, and other experts on our staff.

FDA Revokes Approval of Avastin for Breast Cancer

Associated Press, November 18, 2011. Dr. Diana Zuckerman, tells AP about the problems with Avastin.

Lawmakers May Relax FDA Drug Conflict Rules

Reuters, November 1, 2011. Dr. Diana Zuckerman, president of the National Research Center for Women & Families, talks about the need for stronger conflict of interest rules for the FDA.

Birth-Control Pills Tied to Dangerous Clots: Which Brands?

CBS News, October 27, 2011. Dr. Diana Zuckerman, president of the National Research Center for Women & Families, questions why the FDA approves birth control pills that are less safe and have no benefit compared to drugs already on the market.

FDA says Yaz and Other Next-Generation Birth Control Drugs Appear to Increase Blood Clot Risk

The Republic, October 27, 2011. NRC President, Dr. Diana Zuckerman tells the Republic about problems with the popular birth control Yaz. She questions why you would take Yaz, the more expensive option that can potentially kill you.

J&J Vaginal Mesh Approved by FDA Based on Similar Device Recalled in 1999

Bloomberg, October 20, 2011. President of the National Research Center for Women & Families Dr. Diana Zuckerman told Bloomberg that the 501(K) FDA approval process has become a gateway for high-risk medical devices such as joint implants and vaginal mesh that can claim a tie to older products.